There’s more bad news for β-secretase 1 (BACE1) inhibitors, a class of Alzheimer disease (AD) drug designed to reduce amyloid plaques by controlling amyloid processing upstream of anti-amyloid antibodies and of γ-secretase inhibitors. Just weeks after Merck & Co. published the results of its failed pivotal trial of verubecestat in mild-to-moderate AD, Johnson & Johnson and partner Shionogi have terminated late-stage development of atabecestat in asymptomatic individuals owing to safety concerns…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JUNE 2018 | 385